Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

COV-BARRIER Study Group

Research output: Contribution to journalArticlepeer-review

264 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences